首页> 外文期刊>Biological psychiatry >Electroencephalography and Event-Related Potential Biomarkers in Individuals at Clinical High Risk for Psychosis
【24h】

Electroencephalography and Event-Related Potential Biomarkers in Individuals at Clinical High Risk for Psychosis

机译:在临床高风险的个人心理学中脑电图和事件相关的潜在生物标志物

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Clinical outcomes vary among youths at clinical high risk for psychosis (CHR-P), with approximately 20% progressing to full-blown psychosis over 2 to 3 years and 30% achieving remission. Recent research efforts have focused on identifying biomarkers that precede psychosis onset and enhance the accuracy of clinical outcome prediction in CHR-P individuals, with the ultimate goal of developing staged treatment approaches based on the individual's level of risk. Identifying such biomarkers may also facilitate progress toward understanding pathogenic mechanisms un-derlying psychosis onset, which may support the development of mechanistically informed early interventions for psychosis. In recent years, electroencephalography-based event-related potential measures with established sensitivity to schizophrenia have gained traction in the study of CHR-P and its clinical outcomes. In this review, we describe the evidence for event-related potential abnormalities in CHR-P and discuss how they inform our under-standing of information processing deficits as vulnerability markers for emerging psychosis and as indicators of future outcomes. Among the measures studied, P300 and mismatch negativity are notable because deficits predict con-version to psychosis and/or CHR-P remission. However, the accuracy with which these and other measures predict outcomes in CHR-P has been obscured in the prior literature by the tendency to only report group-level differences, underscoring the need for inclusion of individual predictive accuracy metrics in future studies. Nevertheless, both P300 and mismatch negativity show promise as electrophysiological markers of risk for psychosis, as target engagement measures for clinical trials, and as potential translational bridges between human studies and animal models focused on novel drug development for early psychosis.
机译:临床结果在精神病(CHR-P)的临床高风险上的青少年之间变化,大约20%以上的精神病程度超过2〜3岁,达到缓解30%。最近的研究努力侧重于识别精神病疾病的生物标志物,并提高CHR-P个体中临床结果预测的准确性,基于个人风险水平发展分阶段治疗方法的最终目标。确定这些生物标志物还可以促进理解致病机制的进展,这可能支持机械主义知识的早期干预措施对精神病的发展。近年来,基于脑电图的事件相关的潜在措施,其对精神分裂症的敏感性的敏感性措施在CHR-P研究及其临床结果的研究中获得了牵引力。在这篇综述中,我们描述了CHR-P中与事件相关的潜在异常的证据,并讨论了他们如何通知信息处理赤字作为新兴精神病的脆弱性标志,并作为未来结果的指标。在研究的措施中,P300和不匹配的消极性是值得注意的,因为缺陷预测心理到精神病和/或CHR-P缓解。然而,这些和其他措施预测CHR-P中的结果的准确性通过仅报告组级别差异的趋势在现有的文献中被揭示,强调了在未来的研究中包含个人预测准确度指标的需要。然而,P300和不匹配的消极性显示出作为精神病风险的电生理学标志,作为临床试验的目标接合措施,以及人类研究和动物模型之间的潜在翻译桥梁,专注于早期精神病的新药开发。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号